Sign inJoin waitlistJoin the waitlist

Michael Harrison

Associate Professor of Medicine · Duke University Hospital

Credentials: · · · ·

History

University of Wisconsin School of Medicine and Public Health
2007–2009
Internal Medicine
Duke University Hospital
2004–2007
Internal Medicine
Tulane University School of Medicine
2004–2007
Tulane University School of Medicine
2000–2004

Research

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
Journal of Clinical Oncology · 2015 · 901 citations
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised,…
The Lancet Oncology · 2019 · 646 citations
Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2017 · 413 citations

Daniel George
52 papers
Andrew Armstrong
36 papers
Tian Zhang
26 papers · 2 as a fellow
Sundhar Ramalingam
13 papers
Brant Inman
9 papers
Matthew Milowsky
9 papers
Toni Choueiri
8 papers
Rajan Gupta
7 papers
AA
Amy Abernethy
6 papers
BH
Bradford Hirsch
6 papers
Elizabeth Plimack
6 papers
Hannah Dzimitrowicz
6 papers · 3 as a fellow

Clinical trials

Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer
Principal investigator · Terminated · Phase 2
Duke University
2020–2021
A Survivorship Care Plan and Embedded Navigation Tool
Principal investigator · Completed
Duke University
2019–2020
INTERVAL: Ipilimumab and Nivolumab Combination Therapy: A Study of a Supervised or Semi-Supervised Exercise InteRVention or Usual Care With Functional Capacity and Quality of Life Evaluations in Subjects With Advanced or Metastatic RenAL Cell Carcinoma
Principal investigator · Terminated
Duke University
2018–2019
Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing
Principal investigator · Completed · Phase 2
Duke University
2017–2019